Five Prime Therapeutics Reports First Quarter 2020 Results
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) shareholders will doubtless be very grateful to see the share price up 33...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Five Prime Therapeutics Changes 2020 Annual Meeting to Virtual Format
Q1 2020 Five Prime Therapeutics Inc Earnings Call
Largest insider trades of the week Continue reading...
Five Prime Therapeutics Appoints Tom Civik as Chief Executive Officer
New York-born, Bay Area-raised Brian Wong is doing the hard work of broadening a drug pipeline with what he describes as a “Brooklyn toughness."
Q3 2019 Five Prime Therapeutics Inc Earnings Call
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees in 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]
Largest insider trades of the week Continue reading...
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -8.42% and -31.02%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology
Five Prime Therapeutics Announces Timing of Its First Quarter 2020 Results Conference Call
Five Prime Therapeutics (FPRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 8.25% and -20.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Lewis "Rusty" Williams founded Five Prime Therapeutics nearly 20 years ago. Now he, the co-inventor of the cancer drug Opdivo and two other Five Prime executives are deep into a new startup.
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) just released its first-quarter report and things are looking bullish...
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Q4 2019 Five Prime Therapeutics Inc Earnings Call